Daiichi Sankyo Dec 8, 2022 Daiichi Sankyo Transfers Rights to Market Yescarta in Japan to Gilead Sciences Dec 8, 2022 New HER2-Low Category Spurring Efforts to Understand Breast Cancer Biology, Develop Better Tests Premium Dec 7, 2022 SABCS Data Solidifies Enhertu as Preferred Second-, Third-Line HER2-Positive Breast Cancer Treatment Premium Nov 14, 2022 EMA's CHMP Recommends Enhertu for HER2-Positive Gastric Cancer Oct 4, 2022 FDA Approves Roche Antibody Test as CDx for Enhertu in HER2-Low Breast Cancer Patients Sep 29, 2022 Consortium Aims to Standardize IHC Biomarker Tests for Precision Medicine, Starting With HER2 Premium Aug 26, 2022 In Brief This Week: Immatics, Aktis Oncology, Daiichi Sankyo, Roche Pharma India, Genetron Aug 12, 2022 AstraZeneca, Daiichi Sankyo's Enhertu Scores FDA Accelerated Approval in HER2-Mutant Lung Cancer Aug 11, 2022 New Drugs Going After 'Achilles' Heel' Resistance Mutation in NSCLC Premium Aug 9, 2022 GSK, Mersana Therapeutics Ink $100M Option Agreement for Antibody-Drug Conjugate Aug 5, 2022 FDA Approves Enhertu for HER2-Low Metastatic Breast Cancer Jul 29, 2022 AstraZeneca Q2 Oncology Sales Grow 14 Percent as Firm Awaits Key Precision Drug Regulatory Decisions Premium Jul 19, 2022 Enhertu Racks Up Another EU Approval in Second-Line HER2-Positive Metastatic Breast Cancer Jul 18, 2022 Byondis, Medac File for European Approval of SYD985 for HER2-Positive Breast Cancer Jun 27, 2022 EMA's CHMP Backs Approval for Enhertu, Lynparza for Two Breast Cancer Indications Jun 22, 2022 Daiichi Sankyo's Application for Enhertu in HER2-Low Breast Cancer to Commence European Review Jun 13, 2022 Daiichi Sankyo, AstraZeneca Begin Phase III Trial of Datopotamab Deruxtecan for TNBC Jun 6, 2022 Enhertu Benefit in HER2-Low Breast Cancer Wows at ASCO; Signals Shifting Therapy, Dx Paradigms May 26, 2022 UK Researchers ID Potential Biomarker of Response to Herceptin in Overweight Breast Cancer Patients Premium May 11, 2022 Strata Oncology Enrolling Patients in Basket Trial Exploring Biomarker-Defined Indications Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
